Skip to main content
Equibles
HCM logo

HCM · HUTCHMED (China) Ltd

Track HCM — free

Use HCM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.04 +0.13 (+1.09%) At close · Sep 2
Rebalance outlook locked
Market Cap
$2.07B
Shares
173.81M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.04 Open$11.95 Day$11.95–12.15 52W close$9.99–17.93 Avg vol 30d59K Short int170K · 0.1% float · 4.5d Short vol26% Last earningsJul 30, 2026 DataJan 2020–Sep 2026

Up next

Next earnings call
Jan 28, 2027 Est · unconfirmed · in 21 wks

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-20.7%
Trailing year
Short interest
0.1%
Latest settlement · 4.5 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg +4%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 26%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +4%
trailing
6-month return −15%
trailing
YTD return −10%
this year
Relative strength −30%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.10% of float · ▼ -6.1% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — mid 3-yr range
Squeeze score 50
elevated · 0–100
Fundamentals
Strong
Revenue growth +20%
Y/Y
EPS growth +1200%
Y/Y
Free cash flow $-78.8M
Balance sheet $46.8M
net debt
Quant / Vol
risk profile
High
Volatility 35%
annualized · 1-yr
Max drawdown −44%
past year
ATR 2.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
+4% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
26% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.10% of float · ▼ -6.1% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $10 Now $12 · 26% Range high $18
vs 200-day avg -9% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HCM
HUTCHMED (China) Ltd
this stock
$2.07B -9.7% +19.7% — 0.1%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.66B +18.2% — — 0.1%
GALDY
Galderma Group AG/ADR
 $47.69B -1.7% — — 0.0%
HLN
Haleon plc
 $44.35B -2.0% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
56
% held
2.5%
Net QoQ
+51.8K sh
Top holder
SCHRODER INVESTMENT MANAG…
Held Float
View
Held by Funds
Fund positions
21
View
Short & Settlement
Short Interest Falling
Shares short
169.6K
Days to cover
4.5d
Change
-11.0K sh
View
Short Volume
Short vol %
26%
As of
Sep 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$16.8K
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
39.1%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$548.5M
Net income (FY)
$456.9M
EPS diluted
$0.52
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 31, 2026
This year
30
View
Earnings & Events
Earnings Calls
Last call
Jul 30, 2026
View

Performance

5D 20D 120D MTD YTD
HCM -2.5% +4.2% -15.2% -0.7% -9.7%
SPY -0.1% -0.6% +14.9% -0.3% +12.2%
vs SPY -2.4% +4.8% -30.0% -0.4% -21.9%
Key facts CIK 1648257 CUSIP 44842L103 13F (30d) 47 filings 47 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)